Incremental Effects of Eicosapentaenoic Acid on Cardiovascular Events in Statin-Treated Patients with Coronary Artery Disease

This analysis examined the secondary prevention arm of the Japan EPA Lipid Intervention Study (JELIS) — 18,645 Japanese patients on statins — to determine whether adding EPA reduced coronary events in those with established coronary artery disease.

In the statin-treated CAD subgroup, EPA significantly reduced major coronary events: 15.0 percent versus 20.1 percent over five years (HR 0.73, p=0.033). The benefit was concentrated in patients with prior MI, where the reduction was most pronounced. This incremental benefit on a background of statin therapy is clinically meaningful because it addresses residual risk — the substantial event burden that persists even in statin-treated secondary prevention patients.

The JELIS trial, from which this analysis derives, is distinctive for being the largest EPA trial in a Japanese population, where dietary EPA intake at baseline was already substantially higher than in Western populations. Whether the absolute benefit translates to populations with lower baseline EPA intake remains uncertain. The drug used (icosapent ethyl, pure EPA) is also distinct from combined EPA+DHA formulations that have produced inconsistent results.

We rate the evidence strong in the context of EPA pharmacology. A large secondary prevention RCT in statin-treated patients demonstrating significant incremental benefit — consistent with the subsequent REDUCE-IT trial, which confirmed icosapent ethyl’s cardiovascular benefit in a Western population.